Subscription
Last updated on 16-May-2025 18:32:02
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIB | 141600 | 1719600 | 12.14 |
| NIB | 1222800 | 5244000 | 4.29 |
| RETAIL | 1222800 | 12895200 | 10.55 |
| Total | 2587200 | 19858800 | 7.68 |
| Application Wise Breakup | |
|---|---|
| Category | App. Received |
| QIB | 4 |
| NIB | 889 |
| RETAIL | 10746 |
| Total | 11639 |
| Subscription Demand (in ₹ crore) | |||
|---|---|---|---|
| Category | Offered | Demand | Times |
| QIB | 1.43 | 17.37 | 12.14 |
| NIB | 12.35 | 51.47 | 4.17 |
| RETAIL | 12.35 | 130.24 | 10.55 |
| Total | 26.13 | 199.08 | 7.62 |
| QIB Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹1.6 | @8% ₹1.9 | @9% ₹2.1 | @10% ₹2.4 | @11% ₹2.6 | @12% ₹2.8 |
| HNI Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹0.6 | @8% ₹0.6 | @9% ₹0.7 | @10% ₹0.8 | @11% ₹0.9 | @12% ₹1 |
About
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail | 1 | 1200 | 121200 | 1019 |
| HNI | 2 | 2400 | 242400 | 1019 |
IPO Reservation
| Investor Category | Shares Offered | No. of Shares |
|---|---|---|
| Retail | 41.51% | 1222800 |
| HNI | 41.51% | 1222800 |
| Anchor | 7.17% | 211200 |
| QIB | 4.81% | 141600 |
| Market Maker | 5.01% | 147600 |
| Total | 100.00% | 2946000 |
Accretion Pharmaceuticals IPO Details
| Issue Size | 29,46,000 shares (aggregating up to ₹29.75 Cr) |
| Fresh Issue | 29,46,000 shares (aggregating up to ₹29.75 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 81,70,000 shares |
| Share Holding Post Issue | 1,11,16,000 shares |
| Market Maker Portion | 1,47,600 shares |
| Market Maker | Gretex Share Broking |
Key Performance Indicator (KPI)
| KPI | Dec-24 | Mar-24 | Mar-23 |
|---|---|---|---|
| ROE | 38.54% | 72.47% | 2.70% |
| ROCE | 30.14% | 36.73% | 9.87% |
| RONW | 38.54% | 72.47% | 2.70% |
| EPS (basic) | 8.74 | 9.69 | 0.26 |
| P/E Pre IPO | 21.29 | ||
| P/E Post IPO | 16.08 |
Company Financials In Crores
| Period Ended | Dec-24 | Mar-24 | Mar-23 | Mar-22 |
|---|---|---|---|---|
| Assets | 40.0 | 27.1 | 20.6 | 17.7 |
| Revenue | 35.8 | 33.9 | 29.5 | 22.6 |
| Profit After Tax | 5.2 | 3.9 | 0.1 | 0.1 |
| Net Worth | 13.6 | 5.4 | 3.8 | 3.1 |
| Reserves and Surplus | 5.4 | 1.4 | 0.0 | 0.0 |
| Total Borrowing | 13.8 | 13.5 | 8.5 | 7.6 |
Company Overview
Name: Accretion Pharmaceuticals Limited
Founded: 2012
Headquarters: Ahmedabad-Sanand, Gujarat, India
Industry: Pharmaceuticals (Formulations + Contract Manufacturing)
Employee Strength: 83 (including 4 Executive Directors, as of January 2025)
Core Business & Offerings
Product Portfolio:
Tablets/Capsules: Antibiotics, anti-inflammatory, cardiovascular, and gastrointestinal drugs.
Oral Liquids/Syrups: Pediatric, respiratory, and digestive treatments.
External Preparations: Ointments, creams, medicated shampoos, dusting powders.
Ayurvedic/Herbal: Natural wellness products for immunity and digestion.
Services: Contract Manufacturing for third-party brands.
Utilization of Funds
Growth-Oriented Capex (₹73.53M Total: 1+2)
Financial Prudence (₹9.92M Debt Repayment)
Working Capital Dominance (₹146.8M – 64% of Total)
Flexibility (General Corporate Purposes)
Modernization: Upgrading facilities and new machinery will boost production capacity and export readiness (key for 20+ country footprint).
Quality Compliance: Reinforces adherence to ISO/GMP standards, appealing to global clients.
Low Leverage: Minimal debt repayment suggests already lean balance sheet, reducing post-IPO financial risk.
Scalability Focus: Funds will ensure smooth operations amid expansion, especially for contract manufacturing and export orders.
Liquidity Cushion: Mitigates cyclical cash flow challenges in pharma.
Potential uses: R&D, market expansion, or acquisitions
Strength
Experienced Promoters and Management Team – Led by a knowledgeable leadership team with deep industry expertise.
Established Client and Supplier Relationships – Maintains strong, long-term partnerships ensuring business stability.
Weakness
Outstanding Litigation – Ongoing legal proceedings may negatively impact the company’s reputation and financial performance.
Regulatory Compliance – Non-compliance with evolving pharmaceutical regulations could disrupt operations and affect business continuity.
Regulatory Inspections – Adverse findings from inspections or audits by authorities or clients may lead to penalties or reputational harm.
AVOID THIS IF YOU CANT AFFORD RISK
Lead Manager(s)
Address
29 Xcelon Ind Park 1,
B/h, Intas Pharmaceuticals, Vasna Chacharvad
Sanand,
Phone: +91-97148 82929
Email: compliance@accretionpharma.com
Website: https://accretionpharma.com/